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Contralaterally transplanted human embryonic stem
cell-derived neural precursor cells (ENStem-A) migrate
and improve brain functions in stroke-damaged rats
Da-Jeong Chang1,6, Seung-Hun Oh2,6, Nayeon Lee1, Chunggab Choi1, Iksoo Jeon1, Hyun Sook Kim2,
Dong Ah Shin3, Seo Eun Lee4, Daehong Kim5 and Jihwan Song1,2
The transplantation of neural precursor cells (NPCs) is known to be a promising approach to ameliorating behavioral deficits
after stroke in a rodent model of middle cerebral artery occlusion (MCAo). Previous studies have shown that transplanted NPCs
migrate toward the infarct region, survive and differentiate into mature neurons to some extent. However, the spatiotemporal
dynamics of NPC migration following transplantation into stroke animals have yet to be elucidated. In this study, we
investigated the fates of human embryonic stem cell (hESC)-derived NPCs (ENStem-A) for 8 weeks following transplantation
into the side contralateral to the infarct region using 7.0T animal magnetic resonance imaging (MRI). T2- and T2*-weighted
MRI analyses indicated that the migrating cells were clearly detectable at the infarct boundary zone by 1 week, and the
intensity of the MRI signals robustly increased within 4 weeks after transplantation. Afterwards, the signals were slightly
increased or unchanged. At 8 weeks, we performed Prussian blue staining and immunohistochemical staining using human-
specific markers, and found that high percentages of transplanted cells migrated to the infarct boundary. Most of these cells
were CXCR4-positive. We also observed that the migrating cells expressed markers for various stages of neural differentiation,
including Nestin, Tuj1, NeuN, TH, DARPP-32 and SV38, indicating that the transplanted cells may partially contribute to the
reconstruction of the damaged neural tissues after stroke. Interestingly, we found that the extent of gliosis (glial fibrillary acidic
protein-positive cells) and apoptosis (TUNEL-positive cells) were significantly decreased in the cell-transplanted group,
suggesting that hESC-NPCs have a positive role in reducing glia scar formation and cell death after stroke. No tumors formed in
our study. We also performed various behavioral tests, including rotarod, stepping and modified neurological severity score tests,
and found that the transplanted animals exhibited significant improvements in sensorimotor functions during the 8 weeks after
transplantation. Taken together, these results strongly suggest that hESC-NPCs have the capacity to migrate to the infarct
region, form neural tissues efficiently and contribute to behavioral recovery in a rodent model of ischemic stroke.
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INTRODUCTION
Stroke is one of the leading causes of death and disability
worldwide. Although thrombolytic treatments, such as tissue
plasminogen activator, are effective for the treatment of stroke,
o10% of stroke patients benefit from this type of treatment
because of its narrow therapeutic time window (within 4.5 h
after onset).1 Despite extensive research using animal models,
no neuroprotective agent has been demonstrated to be
effective in the recovery of primary or secondary damage
following stroke in clinical trials.2
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In animal models of stroke, the transplantation of neural
precursor cells (NPCs) has been shown to be a promising
approach to ameliorate behavioral deficits. Recently, the first
clinical trial using NPCs in stroke patients was performed by
ReNeuron using clonal, conditionally immortalized neural
stem cells isolated from human fetal cortex, and the pre-
liminary report suggests that the NPC transplantation is safe.3
Most previous experimental studies have indicated that NPCs
transplanted into the ipsilesional cerebral hemisphere before or
after stroke underwent robust targeted transparenchymal
migration toward the lesion boundary.4–7 This intriguing
phenomenon may be orchestrated by multiple factors or the
host environment, which is not fully understood. Several
studies have also shown that embryonic stem cells or NPCs
that were transplanted into the side contralateral to the
cerebral infarction also migrate toward the lesion and
survive.8–10 This result indicates that a strong, long-range
chemotactic gradient sufficient to induce travel from the
implantation site to the lesion site may be present.
In vivo cellular imaging techniques, such as magnetic
resonance imaging (MRI) of supraparamagnetic iron oxide
particle-labeled stem cells, enable the analysis of stem cell
migration over the long periods of time in the same subject
following transplantation.11,12 Unlike conventional end-point
histology, in vivo MRI offers an opportunity to longitudinally
monitor the implanted cells in vivo, allowing a direct
assessment of the spatiotemporal dynamics of cell migration
and survival following transplantation. However, there have
been only a few studies regarding the long-term dynamic
process of NPC migration using in vivo animal MRI.
In this study, we used a 7.0T animal MRI to track the fates
of human embryonic stem cell (hESC)-derived NPCs
(ENStem-A) labeled with ferumoxides (Feridex)–protamine
sulfate complex following transplantation into a rodent stroke
model up to 8 weeks. In addition, we evaluated whether the
migrating NPCs to the lesion site can survive, differentiate into
various types of neurons and contribute to functional
improvement in a rodent model of ischemic stroke.
MATERIALS AND METHODS
Culture and characterization of hESC-NPCs (ENStem-A)
For this study, we purchased the hESC-NPC line, ENStem-A, from
Millipore (Billerica, MA, USA). ENStem-A is a neural progenitor cell
line derived from H9 hESCs. The ENStem-A cells were cultured
according to the manufacturer’s instructions. Briefly, they were incubated
in ENStem-A Neural Expansion Medium (Chemicon, Temecula, CA,
USA) supplemented with fibroblast growth factor-2 (20ngml1). To
analyze the in vitro marker expression of ENStem-A cells, we performed
immunocytochemical analyses using the following primary antibodies:
SOX2 (1:200, Chemicon), neural cell adhesion molecule (1:500, Che-
micon), human-specific Nestin (1:250, R&D Systems, Minneapolis, MN,
USA) and Musashi (1:500, Chemicon). The secondary antibodies used
were Alexa 555-conjugated goat anti-mouse IgG (1:200, Molecular
Probes, Eugene, OR, USA) and Alexa 488-conjugated goat anti-rabbit
IgG (1:200, Molecular Probes). The staining patterns were examined and
photographed using a confocal laser scanning microscope imaging
system (LSM510, Carl Zeiss, Inc.,Thornwood, NY, USA).
For reverse transcription-PCR analysis, we isolated total RNA from
cells using the TRIzol RNA extraction method (Gibco, Gaithersburg,
MD, USA) and synthesized complementary DNA using M-MLV
reverse transcriptase (Promega, Madison, WI, USA) at 42 1C for 1 h.
PCR amplification was performed using Taq polymerase according to
the manufacturer’s instructions (Intron Biotechnology, Gyeonggi-do,
Korea). Below is the following information for the primers used
in this study: sequences, GenBank accession numbers, expected
product sizes, and annealing temperatures. All PCR reactions
included 30 cycles of amplification.
Sox2 (NM_003106): forward (F): 50-GCTGCAAAAGA
GAACACCAA-30, reverse (R): 50-CTTCCTGCAAAGCTCCTACC-30
(232 bp, 59 1C); Nestin (NM_006617): F: 50-TCCAGAAACTCAAGCA
CCA-30, R: 50-AAATTCTCCAGGTTCCATGC-30 (183 bp, 59 1C); IIIb-
tubulin (BC000748.2): F: 50-ATGAGGGAGATCGTGCACAT-30, R: 50-
GCCCCTGAGCGGACACTGT-30 (239 bp, 59 1C); Map2 (U01828): F:
50-GCATATGCGCTGATTCTTCA-30, R: 50-CTTTCCGTTCATCTG
CCATT-30 (202 bp, 59 1C); GFAP (BC041765.1): F: 50-GCAGAGAT
GATGGAGCTCAATGACC-30, R: 50-GTTTCATCCTGGAGCTTCT
GCCTCA-30 (266bp, 59 1C); and GAPDH (BC083511.1): F: 50-
GTCATACCAGGAAATGAGCT-30, R: 50-TGACCACAGTCCATGC-
CATC-30 (422 bp, 60 1C).
Generation of the rodent MCAo model and cell
transplantation
The manipulation of the experimental animals was performed in
accordance with the guidelines of the CHA University IACUC
(Institutional Animal Care and Use Committee; IACUC090012).
Adult male Sprague–Dawley rats (Orient, Seoul, Korea) weighing
270 to 300 g were used in this study. The rats were housed with access
to food and water ad libitum under a 12-h light/dark cycle. After the
rats had been anesthetized with 1% ketamine (30mg kg1, intraper-
itoneal) and xylazine hydrochloride (4mg kg1, intraperitoneal), we
maintained the rats’ body temperatures at 37±1 1C using a rectal
probe and a heating pad. To induce middle cerebral artery occlusion
(MCAo), we used the method of Longa et al.13 A blunt-ended
monofilament (4–0, Ethicon, Livingston, Scotland, UK) was inserted
into the internal carotid artery from the bifurcation to occlude the
middle cerebral artery. The monofilament was carefully removed
90min after MCAo induction.
On the next day, we assessed the acute neurological severity using
circling behavior and forelimb/hindlimb placement tests to select the
appropriate stroke animals. For transplantation, animals were divided
into the transplantation group, which received 2 105 hESC-NPCs
(ENStem-A) in a total volume of 2ml (n¼ 8), and the sham group,
which received 2ml of culture medium (n¼ 6). At 1 week after MCAo
induction, ENStem-A cells were transplanted into the contralateral
side in the striatum region using the following stereotaxic coordinates:
1.0mm anteroposterior, 3.0mm mediolateral and 5.0mm dorsoven-
tral from the bregma. The 26-gauge Hamilton syringe (Reno, NV,
USA) was left in place for an additional 5min to stabilize the
transplanted cells. All rats received cyclosporine A (Sigma, St Louis,
MO, USA, 10mgkg1, intraperitoneal) for immunosuppression from
1 day before transplantation until the end of the observation period
for 8 weeks after transplantation.
Behavioral tests
All animals were trained under the same conditions three times a day
for three consecutive days before the induction of MCAo to minimize
variation among the animals. In the rotarod test, in which the rod
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speed progressively increased from 4 to 40 r.p.m. for 2min, all rats
were placed on the rotarod cylinder, and the time that each rat
remained on the cylinder was recorded. Each week for 8 weeks after
transplantation, we recorded the time when the animals fell off the
rotating rod, and we calculated the average time (in seconds) for three
trials. In the stepping test, all rats were initially familiarized with the
experimenter’s grip. The number of forepaw placements was counted
for each rat to assess akinesia, when they were moved slowly in both
forehand and backhand directions along the edge of a table over a
distance of 90 cm in 5 sec. All animals were examined weekly for 8
weeks. We also performed the modified neurological severity score test,
the scores of which were interpreted as follows: 0 point, normal; 1–9
points, mild injury; 10–19 points, moderate injury; 20–27 points,
severe injury; 28 points, the most severe condition.
MRI detection of the labeled cells
To label the cells for animal MRI, we used Feridex (Taejoon Pharm,
Seoul, Korea) as a contrast agent. The Feridex–protamine sulfate
complex was prepared at a concentration of 2mgml1 in culture
medium without serum, and this mixture was mixed by hand shaking
and incubated for 30min at room temperature. Then, an equal
volume of culture medium and the Feridex–protamine sulfate complex
was added to the cells, and they were incubated for 12–16h at 37 1C.
The medium was removed, and the cells were washed twice with
phosphate-buffered saline (PBS). All rats were examined to determine
whether the Feridex-labeled ENStem-A cells migrated toward the
ischemic region using a 7.0T MRI (BioSpec 70/20, Bruker, Germany).
The cell locations were assessed for B8 weeks following transplanta-
tion. T2-weighted imaging was used to assess the full extent of the
infarct, and T2* imaging was used to track the location and migration
of the labeled cells. At 8 weeks after transplantation, we performed
Prussian blue staining to detect the Feridex-labeled cells and to track
the contralaterally transplanted stem cells in the ischemic brain.
Immunohistochemical analysis
At 8 weeks after transplantation, the rats were transcardially perfused
with heparinized saline (0.9% NaCl). The brains were fixed in 4%
paraformaldehyde at room temperature overnight, transferred to 30%
sucrose for 1–3 days at 4 1C, and then embedded in optimal cutting
temperature compound (OCT, Sakura Finetek, Tokyo, Japan). Double-
label immunofluorescence staining was performed on free-floating
40mm-thick sections. Sections were incubated in blocking solution,
which consisted of 5% normal horse serum (Vector Laboratories,
Burlingame, CA, USA) in PBS containing 0.3% Triton X-100 (Sigma)
for 1 h at room temperature. The following primary antibodies were
used: human-specific nuclei (hNu) (1:100, Chemicon), human-specific
mitochondria (hMito) (1:250, Chemicon), human-specific Nestin
(1:250, R&D Systems), NeuN (1:500, Millipore), DARPP-32 (1:100,
Cell Signaling Technology, Danvers, MA, USA), tyrosine hydroxylase
(TH) (1:1000, Pel-Freez, Rodgers, AR, USA), synaptophysin (SVP-38)
(1:200, Sigma), and CXCR4 (1:40, R&D Systems). After several washes
in PBS, the brain sections were incubated with the following secondary
antibodies for 2 h at room temperature: Alexa 488- or 555-conjugated
goat anti-mouse IgG or Alexa 488- or 555-conjugated goat anti-rabbit
IgG. Next, the sections were counterstained with the nuclear marker
40,60-diamidino-2-phenylindole (DAPI).
To detect the Feridex-labeled cells in vivo, Prussian staining was
performed. Tissue sections were fixed in methanol for 30min at room
temperature, followed by treatment with a mixture of 4% potassium
ferrocyanide and 4% HCl solution. After boiling, these sections were
washed with PBS, mounted and examined under a light microscope
(Eclipse E600, Nikon, Tokyo, Japan). To detect apoptotic cells, TUNEL
(terminal deoxynucleotidyl transferase-mediated dUTP nick-end label-
ing) assay was performed. Frozen sections were cut and fixed in 4%
paraformaldehyde in PBS for 20min at room temperature. After three
washes in PBS for 30min, the sections were stained using the In Situ
Cell Death Detection Kit (Roche, Indianapolis, IN, USA) according to
the manufacturer’s instructions. All sections were counterstained with
40,60-diamidino-2-phenylindole (DAB). The number of TUNEL-posi-
tive cells per field in the vicinity of the infarct region was quantified
using ImageJ software (NIH, Bethesda, MD, USA).
Statistical analysis
Statistical analysis was performed using the Statistical Analysis System
program (Enterprise 4.1; SAS, Seoul, Korea). All values are presented
as the mean±s.e.m. (standard error of mean). The statistical
significance of the differences between the two groups for the
behavioral scores was analyzed by one-way analysis of variance
(ANOVA). A probability value of o0.05 was considered significant.
RESULTS
Characterization of hESC-NPCs (ENStem-A)
To characterize hESC-NPCs (ENStem-A), we plated them on a
coverslip precoated with laminin. The ENStem-A cells prolifer-
ated as an adherent monolayer. We found that they robustly
express Sox2 (neuroepithelial cell marker), neural cell adhesion
molecule (neural progenitor marker), Nestin (neural stem marker)
and Musashi (neural progenitor marker) (Figures 1a–d). We also
observed that the ENStem-A cells expressed transcripts for neural
precursor markers, such as Sox2 and Nestin, and an early neural
marker, type III-b tubulin (IIIb-tub), whereas there was no
expression of markers of mature neurons, such as microtubule-
associated protein 2 (Map2), or glial cells, such as
glial fibrillary acidic protein (GFAP) (Figure 1e). These results
indicate that ENStem-A cells represent a homogeneous population
of NPCs.
MRI tracking of contralaterally transplanted hESC-NPCs
(ENStem-A) in vivo
To track the location and migration of transplanted hESC-
NPCs in vivo, we intracerebrally transplanted ENStem-A cells
into the striatum on the side contralateral to the ischemic
injury. Figure 2a shows representative T2*-weighted MR
images taken before cell transplantation and at 5, 7, 25, 32,
39, 46 and 53 days after cell transplantation. Using a sequential
series analysis, we examined the distribution of migrated cells
from 2.76mm anterior to -4.36mm posterior to the landmark
position of the bregma (Figure 2a). As early as 5 days after
transplantation into the hemisphere contralateral to the infarct
area, we were able to detect hypointense signals, indicative of
migrating cells, in the ipsilateral side in the T2*-weighted
images for all tested animals. The area of the cell migration
signals on the MR images exhibited a robust increase from 7
days to 25 days after transplantation in most of the examined
animals, and afterwards, no change in the intensity of the cell
migration signals was found up to 53 days after transplanta-
tion. The migrating cells were primarily found at the boundary
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of the infarct lesion (from 1.68mm anterior to 0.48mm
posterior to the bregma), but no signals were detected in the
infarct core, corpus callosum or other cerebral areas by MRI.
After the completion of the in vivo MRI study, the animals
were transcardially perfused, and histological evaluation was
performed. We first performed Prussian blue staining on the
brain sections 53 days after transplantation (B2 months after
the stroke) to determine whether the migrating cells detected
by MRI were the transplanted cells. The Prussian blue staining
specifically detected Feridex-labeled cells at the infarct borders,
where positive cell migration signals were also detected by
T2*-weighted MRI (Figure 2b). In a double-staining confocal
analysis using antibodies against hMito and CXCR4, a chemo-
kine receptor that recognizes inflammatory signals and other
signals, we observed that hMito-positive migrating cells were
colocalized with CXCR4 at the infarct border (Figure 2c). We
also stained the brain sections with hNu antibody to determine
the number of surviving cells, and then counted the number of
hNu-positive cells using unbiased stereology. These cells were
located primarily in the peri-infarct area of the adjacent
striatum, and some hNu-positive cells were also detected in
the corpus callosum (data not shown). The detected hNu-
positive cells were estimated to represent B20%
(B19.97±13.98%) of the initial number of transplanted cells.
Neuronal differentiation of transplanted hESC-NPCs
(ENStem-A) in vivo
We observed that a large percentage of the transplanted
ENStem-A cells that migrated toward the infarct border zone
were still hNestin-positive neural precursor/stem cells
(Figure 3a). The hMito- or hNu-positive cells were found
along the border of the ischemic region. Interestingly, Tuj1-
positive and hMito-positive cells were found in the ischemic
cortex region (Figure 3b). The hMito-positive cells were also
shown to be colocalized with NeuN, a marker of mature
neurons (Figure 3c). We also found that small numbers of the
transplanted cells had differentiated into neurons positive for
TH (Figure 3d) or DARPP-32 (Figure 3e) at the peri-infarct
region of the lateral striatum. The hMito-positive cells were
also colocalized with SVP38, a marker for synaptic vesicle
protein, in the peri-infarct region (Figure 3f).
Functional outcomes of MCAo animals after hESC-NPC
transplantation
All behavior tests were conducted with both the hESC-NPC
(ENStem-A)-transplanted group and the sham group from
postoperative day 3 to 8 weeks after transplantation. There was
no significant difference in the scores for the behavior tests
between the ENStem-A and Sham groups after MCAo induc-
tion. In the rotarod test, MCAo animal models showed severe
impairment. In the ENStem-A group, transplanted animals
showed a slight increase 2 weeks after transplantation com-
pared with the sham group, and this improvement gradually
became more prominent from 3 weeks (Po0.05) to 8 weeks
(Po0.001) after transplantation (Figure 4a). In the stepping
test, the ENStem-A group exhibited significantly improved
performance compared with the sham group only 7 weeks and
8 weeks after transplantation (Po0.001, Figure 4b). In the
modified neurological severity score test, we observed that the
ENStem-A group improved by 1 week after transplantation
compared with the sham group (Po0.05), and the extent of
this improvement became more significant between 4 and
8 weeks after transplantation (Po0.001; Figure 4c).
Reduction of gliosis and apoptosis by transplanted
hESC-NPCs (ENStem-A)
We measured the number of GFAP-positive cells in the peri-
infarct area 8 weeks after transplantation. The ENStem-A
Figure 1 Characteristics of the human embryonic stem cell-derived neural precursor cells (hESC-NPCs, ENStem-A) used in this study.
Immunocytochemical staining showing the expression of neural stem/progenitor makers: (a) Sox2, (b) neural cell adhesion molecule
(NCAM), (c) Nestin and (d) Musashi. The nuclei were counterstained with 40,60-diamidino-2-phenylindole (DAPI; blue). Scale bar, 20mm.
(e) Reverse transcription-PCR (RT-PCR) analysis showing that ENStem-A cells express high levels of Sox2 and Nestin and low levels of
type III-b tubulin (IIIb-tub). The expression of microtubule-associated protein 2 (Map2) and glial fibrillary acidic protein (GFAP) was not
detectable.
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group had a significantly lower number of GFAP-positive cells
in the peri-infarct area compared with the sham group
(29.2±4.4% vs 79.2±4.8%; Po0.01; Figures 5a–c). The
number of TUNEL-positive cells in the peri-infarct area was
also significantly reduced in the ENStem-A group compared
with the sham group (5.6±1.3% vs 23.5±1.7%; Po0.01;
Figures 5d–f). Between the transplanted group and the sham
group, there were no significant differences in the expression
levels of ED1 (microglia and macrophage maker; 28.4±1.5%
vs 23.8±2.7%; P¼ 0.58) and Iba-1 (activated microglia
marker; 26.7±0.6% vs 14.9±1.1%; P¼ 0.31; data not shown).
DISCUSSION
In the present study, we observed the pronounced migration of
hESC-NPCs (ENStem-A) toward the injured site in a rodent
model of ischemic stroke using a serial in vivo animal MRI
analysis over a period of 53 days. The contralaterally trans-
planted cells were detected in the injured brain region, primarily
in the ischemic boundary zone, as early as 5 days after
transplantation, and the migration signals robustly increased
within B1 month after transplantation. This finding was
consistent with those of previous MRI studies on contralaterally
transplanted NPCs.9,10 This finding is also in agreement with
our previous study, in which extensive migration of human
bone marrow-derived mesenchymal stem cells toward the
infarct area was detected.11 It has also been shown that even
systemically administered NPCs can home toward the infarct
area via an unknown mechanism.14 It is conceivable that
there could be multiple factors confounding the real
signals that are solely derived from labeled cells in a stroke-
damaged brain, among which hemorrhage is the most
important factor.
In our study, no hemorrhagic lesions were found in the
histological analysis, and numerous hNu-positive cells were
detected in the infarct boundary up to 8 weeks after trans-
plantation. We also found numerous Prussian blue-positive
cells in the corresponding area, where hypointense signals were
predominantly detected by MRI analysis. An additional con-
founder is the transport of dead Feridex-labeled cells by
macrophages, which could be misinterpreted as cell migra-
tion.15 In this study, we did not quantify the Feridex-labeled
cells phagocytosed by inflammatory cells. However, previous
Figure 2 Detection and visualization of Feridex-labeled human embryonic stem cell-derived neural precursor cells (hESC-NPCs, ENStem-A)
using 7.0T animal magnetic resonance imaging (MRI) and histological methods. (a) Serial T2*-weighted MR images showing the migration
and distribution of the contralaterally transplanted cells. MR images were taken from 5 days to 53 days following transplantation. The red
arrows indicate the cells migrating toward the ischemic peri-infarct region. (b) Hyperintense region in the T2*-weighted MR image
indicating the location of transplanted cells (left) and the corresponding Prussian blue staining, confirming the presence of transplanted
Feridex-labeled cells (shown in blue) (right). (c) Confocal analysis showing that human-specific mitochondria (hMito)-positive migrating
human cells express the chemokine receptor CXCR4. DAPI (40,60-diamidino-2-phenylindole) was used to counterstain the cells. Scale bar,
20mm.
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studies on the contralaterally transplanted fetal NPCs in stroke
models demonstrated that the majority of supraparamagnetic
iron oxide particle-labeled cells (85–90%) were Iba-1-negative
at the infarct boundary zone.10 This result suggests that the
number of migrating cells that were phagocytosed by
inflammatory cells was relatively low. Even in the most
extreme case, some of the transplanted cells can indeed
migrate toward the injured site.
In this study, we demonstrated that the transplanted cells
exhibited a clear directional migration toward the lesion area
using serial MRI analysis. Given the long-distance directed
migration from the transplantation site to the lesion, it has
been postulated that there exists a strong, long-range chemo-
tactic signal with a concentration gradient emanating from the
lesion.9 NPCs possess specific receptors that allow them to
sense gradients of attractive signals generated by the injury site
and to migrate toward the lesion. There is increasing evidence
that chemokines such as stromal cell-derived factor 1 (SDF-1)
regulate the NPC migration after central nervous system injury
and inflammation. Numerous studies have shown that the
interaction of CXCR4, an SDF-1 receptor, with SDF-1 could
play an important role in neural progenitor cell migration.16
Previous in vitro and in vivo studies have demonstrated that
neural progenitor cells express CXCR4 and migrate toward a
source of SDF1, and CXCR4 was expressed by the transplanted
human NPCs migrating to the injured area in the rodent
stroke model.4,17 In the present study, we were also able to
detect CXCR4-positive cells among the migrating cells at the
infarct boundary zone when human embryonic stem cell-
derived NPCs (ENStem-A) were transplanted contralaterally.
Figure 3 Immunohistochemical analyses showing the extent of neuronal differentiation 8 weeks following the transplantation of ENStem-A
cells into middle cerebral artery occlusion (MCAo)-induced rats. Transplanted human cells were identified using antibodies against human-
specific nuclei (hNu) or human-specific mitochondria (hMito), which are shown in red. Transplanted cells were shown to express markers of
neural stem/progenitor cells (Nestin; a) and early and general neurons (type III-b tubulin (Tuj1; b), as well as a neuron-specific nuclear
protein, NeuN (c). They also expressed markers of dopaminergic neurons (tyrosine hydroxylase (TH; d), and medium spiny neurons
(dopamine- and cAMP-regulated neuronal phosphoprotein-32 (DARPP-32; e). Some of the transplanted cells were positive for a synaptic
vesicle protein, SVP38 (f). Scale bar, 50mm.
Figure 4 Behavioral improvement following the transplantation of
ENStem-A cells into middle cerebral artery occlusion (MCAo)-
induced rats. Scores from the rotarod test (a), stepping test (b) and
modified neurological severity score (mNSS) test (c) are shown for
the 8-week study period. MCAo was induced at week 0. The data
are presented as the mean values±s.e.m. The numbers of animals
used in the ENStem-A group and the sham group were 8 and 6,
respectively. *Po0.05 and **Po0.001.
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The exact molecular mechanisms involved in this chemotaxis
or tropism have yet to be elucidated.
Notably, we observed significant functional improvement
following the transplantation of hESC-NPCs (ENStem-A). The
gradual sensorimotor improvement over several weeks after
cell transplantation suggests that the NPCs have a true
recovery-enhancing effect after stroke. In the current study,
B20% of the transplanted cells were detected at the injured
site in the brain, and only a small proportion of the
transplanted cells expressed various types of mature neuronal
markers. Some of the transplanted cells were colocalized with
SVP38, a synaptic vesicle protein, at the infarct boundary zone,
indicating the formation of synapses by the transplanted cells.
It is likely that the functional improvement observed in this
study was mediated by cell replacement by the grafted stem
cells to a certain extent, a hypothesis that is supported by a
previous study in which grafted mouse ESC-NPCs differen-
tiated into mature neurons, as demonstrated by immunohis-
tochemistry and patch clamp studies conducted 12 weeks after
transplantation.5 However, we cannot exclude the possibility
that the cell replacement effect is not the sole mechanism
responsible for the observed functional improvement after
NPC transplantation, primarily because the extent of
differentiation of the transplanted cells into mature neurons
was not sufficiently high to convincingly explain the observed
effects. Furthermore, there was no significant change in the
infarct size after transplantation. Therefore, it is conceivable
that the transplanted cells ameliorated the host environment in
the damaged area via the ‘bystander effect’.
Many previous studies have demonstrated that NPCs
exhibit anti-inflammatory, anti-apoptotic or glial scar-inhibi-
tory effects after brain injury, thereby enhancing functional
recovery.18,19 In support of this notion, the systemic
administration of NPCs has been reported to decrease
inflammation, gliosis and apoptosis following stroke, despite
the extremely low number of cells (o2%) engrafted in the
host brain.14 In the present study, we also observed that the
numbers of GFAP-positive and TUNEL-positive cells were
significantly lower in the NPC-treated rats, suggesting that the
observed functional recovery may have also been mediated by
the anti-gliosis and anti-apoptotic effects of the transplanted
NPCs. However, in the context of inflammation, we observed
no significant differences in the numbers of ED1- or Iba-1-
positive cells between the NPC-treated and sham groups.
Brain inflammation, especially microglial activation, is an
important process leading to secondary neuronal damage and
scar formation following cerebral ischemia, depending on the
time course of stroke.20 Whether NPC transplantation
increases or decreases microglial cell activation14,19,21,22 is still
under debate because of the paucity of data and the differences
in experimental design among the studies. Therefore, we
cannot rule out the possibility that the negative results from
our study are due to the fact that our histological examination
was performed at a late stage (2 months), given that brain
inflammation primarily occurs during the early phase after
stroke (from several days to 3 weeks).23,24 Therefore, further
study is necessary to determine the exact mechanisms
responsible for the effects of hESC-NPCs on brain
inflammation and endogenous neurogenesis, which is
another important aspect of brain recovery, following stroke
using different time courses.
Figure 5 Histological analyses on the extents of gliosis and apoptosis following cell transplantation into middle cerebral artery occlusion
(MCAo)-induced rats. The transplanted group (ENStem-A) exhibited fewer numbers of glial fibrillary acidic protein (GFAP)-positive and
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells in the peri-infarct region 8 weeks after
MCAo compared with the sham group (a–f). Scale bar, 20mm. The data are presented as the mean values±s.e.m. **Po0.001.
Figure 6 A proposed mode of action of the transplanted human
embryonic stem cell-derived neural precursor cells (hESC-NPCs,
ENStem-A) in a rodent model of ischemic stroke.
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In conclusion, we demonstrated that contralaterally trans-
planted hESC-NPCs extensively migrate to and survive in the
infarct region using a serial in vivo MRI analysis in a rodent
model of ischemic stroke. Our study suggests that the long-term
improvement of functional deficits after stroke may be
mediated by neurorestorative (that is, neuronal differentiation
and/or regeneration) and/or neuroprotective effects (that is,
anti-scarring and anti-apoptotic effects) of the transplanted
hESC-NPCs (Figure 6). Further studies on the detailed chemo-
tactic mechanism of hESC-NPCs and optimization of the
therapeutic conditions are necessary to develop more effective
stem cell-based therapies for stroke in the clinical setting.
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